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Abstract 
Background and Aims: Alström syndrome (AS) is a recessive monogenic syndrome 
characterised by obesity, extreme insulin resistance and multi-organ fibrosis. Despite 
phenotypically being high risk of non-alcoholic fatty liver disease (NAFLD), there is a lack 
of data on the extent of fibrosis in the liver and its close links to adipose in patients with AS. 
Our aim is to characterise the hepatic and adipose phenotype in patients with AS. 
Methods: Observational cohort study with comprehensive assessment of metabolic liver 
phenotype including liver elastography (Fibroscan®), serum Enhanced Liver Fibrosis (ELF) 
Panel and liver histology. In addition, abdominal adipose histology and gene expression was 
assessed. We recruited 30 patients from the UK national AS clinic. A subset of 6 patients 
underwent adipose biopsies which was compared with control tissue from 9 healthy 
participants. 
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Results: Patients were overweight/obese (BMI 29.3 (25.95-34.05) kg/m2). 80% (24/30) were 
diabetic. 74% (20/27) had liver ultrasound scanning suggestive of NAFLD. As judged by the 
ELF panel, 96 % (24/25) were categorized as having fibrosis and 10/21 (48 %) had liver 
elastography consistent with advanced liver fibrosis/cirrhosis. In 7/8 selected cases, there was 
evidence of advanced NAFLD on liver histology. Adipose tissue histology showed marked 
fibrosis as well as disordered pro-inflammatory and fibrotic gene expression profiles. 
Conclusions: NAFLD and adipose dysfunction are common in patients with AS. The severity 
of liver disease in our cohort supports the need for screening of liver fibrosis in AS. 
Abstract word count: 237 
Keywords: NAFLD, Alström syndrome, Adipocyte biology, Insulin resistance  
 
 
 
 
Introduction: 
Alström syndrome (AS) is a rare (1 per million) autosomal recessive [OMIM 203800] 
monogenic metabolic syndrome characterised by childhood onset obesity, extreme insulin 
resistance, diabetes, dyslipidaemia, hypertension and multi-organ fibrosis. Other features 
include retinal rod-cone dystrophy, hearing loss, and dilated cardio-myopathy [1]. Alström is 
caused by mutations in ALMS1 gene which encodes an ubiquitously expressed centrosomal 
protein of the primary cilium [2,3]. Cilia are membrane-bound, microtubular projections 
emanating from the cell surface and found on almost all vertebrate cells. Cilia sense a variety 
Key points: 
 Alström Syndrome is a rare autosomal recessive monogenic ciliopathy 
 Liver fibrosis and adipose fibrosis are common in patients with Alström Syndrome 
 The liver fibrosis seen is more advanced than would be anticipated given the young 
age of the patients 
 The liver fibrosis in Alström Syndrome can be identified non-invasively 
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of extracellular signals including hormones transducing them into intracellular signals [4]. 
ALMS1 protein is expressed in key metabolic tissue (liver, skeletal muscle, adipose and 
pancreas). In vitro, ALMS1 deletion is associated with hepatic lipid accumulation [5,6] and 
impaired adipocyte lipid storage [7,8]. Patients with AS have disordered lipid metabolism 
with elevated serum free fatty acids not suppressed by insulin [9] and have insulin resistance 
disproportionate to their BMI [10]. Additionally, we have described premature cardiovascular 
disease in patients with AS [11].  
NAFLD is a is a spectrum ranging from simple steatosis, through to non-alcoholic 
steatohepatitis (NASH), fibrosis and an increased risk of cirrhosis and hepatocellular 
carcinoma. NASH, including cirrhosis and hepatocellular carcinoma, are becoming 
increasingly prevalent mirroring the obesity epidemic [12]. The relationship between obesity 
and NASH is well recognised at a population level, but the mechanism linking obesity to the 
development of NASH remains mostly speculative, partly due to a lack of well-defined 
human disease models. Patients with lipodystrophy, where mutations in several genes result 
in marked loss of adipose tissue mass and perturbed adipocyte function, develop profound 
insulin resistance and accelerated liver disease [13]. These severe hepatic consequences of 
frank anatomical deficiency of adipose tissue have been conceptually linked to the 
consequences of obesity by the notion of "adipose expandability" [14].  It follows that the 
ability of adipose tissue to store excess energy is finite, and when this limit is reached, 
whether at low absolute levels in lipodystrophy or at high absolute levels as in common 
obesity, lipotoxicity of distant organs results. Plausibly the adipose tissue dysfunction seen in 
AS may contribute to the liver phenotype although as ALMS1 is expressed within the liver 
and adipose it may also be via a direct effect of ALMS1 mutation within the liver. 
Case reports and series [1,15–17] as well as our experience within the national AS clinic, 
reveals unexpectedly high incidence of liver cirrhosis and associated morbidity at a young 
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age. We have hypothesised that accelerated NAFLD in AS may relate to extreme insulin 
resistance and be driven (at least in part) by the inability of adipose tissue to provide a 
healthy adipose buffer. We have therefore undertaken the most detailed metabolic 
phenotyping of patients with AS published to date, and performed in-depth analysis of 
metabolic liver disease, incorporating adipose tissue morphology and gene expression 
profiles.  
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Patients and Methods 
Patients and volunteers 
Patients with AS were recruited from the UK National centre for AS service, based at Queen 
Elizabeth Hospital, Birmingham, UK. The diagnosis of AS was confirmed on the basis of 
clinical features and genetic sequencing of ALMS1 gene (Supplementary table S1). 
Informed consent was obtained and the study protocol conforms to the ethical guidelines of 
the 1975 Declaration of Helsinki as reflected in ethical approval by the Cornwall and 
Plymouth NRES (UKCRN 9044, REC approval 10/H0203/33). Data collected included 
patient demographics anthropometric measurements including body mass index (BMI) and 
blood pressure. Clinical phenotypes were recorded as well as details of diabetes status and 
management. A subset of patients consented for adipose tissue biopsy to examine the 
morphology of the adipose tissue and the expression of profibrotic genes. Control adipose 
tissue biopsies were taken from healthy individuals with ethical approval from West 
Midlands-Edgbaston NRES (LREC: 12/WM/0206). The liver biopsies included in this study 
were obtained for clinical reasons. 
Serum analysis 
Liver biochemistry, electrolytes, urea, creatinine, cholesterol, triglycerides, glycated 
haemoglobin, and full blood counts were measured using standard laboratory methods 
(Roche Modular system, Roche Ltd, Lewis, UK). Blood tests were taken in the non-fasting 
state. 
Liver fibrosis 
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Patients underwent an abdominal ultrasound to looking for hepatic steatosis and for structural 
abnormalities associated with more advanced liver disease (splenomegaly, irregular portal 
vein blood flow and an irregular or nodular liver). Serum samples from AS patients were 
analysed for the Enhanced Liver Fibrosis panel (ELF), a well validated non-invasive 
biomarker to identify fibrotic liver disease [18].  Transient elastography was performed using 
Fibroscan® (Echosens, France). Only valid liver stiffness evaluations (LSEs) were recorded 
as per manufacturers guidance (10 readings, IQR <30% of the median LSE, success rate 
>60%).  The cut-off of >7.9kPa was chosen as predictive for fibrosis as this has been shown 
to correlate well with histological findings in NAFLD [19]. 
Histological analysis of liver and adipose tissues 
Liver histology was available for retrospective, review of the diagnosis, fibrosis stage 
(Kleiner) and NAFLD Activity Score (NAS) in 5 Alström syndrome patients and an 
additional 3 more histology reports were available for analysis. Liver biopsies were clinically 
indicated. 
Six (20%) patients with AS and 9 controls had an abdominal subcutaneous adipose tissue 
biopsy performed under local anesthetic (1-2mL of 1% lidocaine), to obtain approximately 
250-500mg of adipose tissue. The patients with AS who had adipose tissue biopsies were 
representative of the cohort as a whole (Supplementary table 2). The samples were divided 
into two and either placed in RNALater® (Ambion Inc., Austin, TX, USA) (initially for 24h 
at room temperature and then at -20ºC) for subsequent gene expression analysis or placed 
into formalin for histological analysis.  
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Adipose tissue histology and gene expression  
Adipose biopsies that were formalin-fixed were embedded in paraffin and cut at a thickness 
of 4µm on a Leica RM2235 microtome (Leica, Milton Keynes, UK) and stained with H&E 
and Van Gieson's to assess fibrosis.   
RNA was prepared using RNeasy Lipid Tissue (QIAGEN). cDNA was generated from the 
RNA (QIAGEN RT² First Strand Kit) and expression of profibrotic genes was assessed using 
real-time reverse transcription array (RT² Profiler™ Arrays: Human fibrosis). 
Statistical analysis 
Unless otherwise stated data expressed is median (interquartile range). Gene expression data 
were obtained as Ct values (Ct is the cycle number at which logarithmic PCR plots cross a 
calculated threshold line) and used to determine ΔCt values [ΔCt = (Ct of the target gene) − 
(Ct of the housekeeping gene)]. Fold change was calculated as 2^ -ΔΔCt [ΔΔCt = (ΔCt of the 
control group) − (ΔCt of the patient group)]. Gene expression was analysed using available 
online software (http://www.sabiosciences.com/pcrarraydataanalysis.php). 
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Results 
Demographic, genetic and metabolic characteristics 
Demographic, anthropometric and metabolic data are presented in Table 1 (mutation analysis 
Supplementary Table 1). Patients were predominantly male 70% (21/30) with a median age 
of 24 (21.5-37) years and a BMI of 29.3 (25.95-34.05) kg/m2. The diabetes prevalence within 
the cohort was 80% with the duration of diabetes 11 (7.5-14.75) years. The prevalence of 
dyslipidaemia was high (total cholesterol 4.95 (4.2-6.3) mmol/L; high density lipoprotein 
cholesterol 0.89 (0.75-1.06) mmol/L; mean triglycerides 3.25 (2.1-4.75) mmol/ L). C-peptide 
to glucose ratios were elevated consistent with the anticipated insulin resistance and 
preserved β-cell function (4.72 (2.67-8.75) (ng/ml)/(mg/dl)*100).  
Hepatic phenotype 
Hepatic phenotypic data for individual patients is provided in Table 2 with histology 
presented in Figure 1 and Table 3.  Median AST and ALT 32 (26-44) and 50 (33-76) IU/ L, 
respectively. 27/30 patients underwent abdominal ultrasound scanning. 20 of 27 (74%) had 
either an echobright liver consistent with hepatic steatosis or features suggestive of more 
advanced disease; in the absence of excess alcohol intake. Of these, 6 patients had 
splenomegaly (>13.5 cm) and 6 had ultrasound features suggestive of advanced fibrosis 
(coarse echotexture, irregular contour). The Enhanced Liver Fibrosis panel was performed in 
25 patients, of whom 96 % were categorized as having either moderate or severe fibrosis. 21 
patients underwent hepatic elastography (Fibroscan®, Echosens, France) with a valid liver 
stiffness evaluations (LSE), 48% (10/21) had a LSE of ≥7.9 kPa suggestive of hepatic 
fibrosis [20]. 
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Formal histological analysis was available in 5 patients (17% study subjects) including the 
Kleiner fibrosis score and NAFLD activity score (Table 3). Additionally 2 post mortems and 
1 liver biopsy report were available for inclusion although the tissue was not available for 
central reporting with Kleiner fibrosis score. These 2 post mortems confirmed cirrhosis of the 
liver with varices in these patients and the biopsy showed extensive fibrosis. In addition, 
subject 10 who is 19 years old had a liver biopsy at the age of 8 with extensive steatohepatitis 
predating diabetes by 9 years, indicating early onset severe NAFLD. 
Adipose tissue gene expression and histology 
The sub-group of patients who underwent adipose tissue biopsy (n=6, male/female=4/2) were 
representative of the AS cohort (Supplementary Table S2). The control volunteers (n=9) 
were exclusively female but were BMI- and age-matched to the patients. 
Histology 
Adipose tissue architecture and morphology were disrupted in patients with AS. Throughout 
the biopsies, there was extensive fibrosis evident on H & E staining (Figure 2b.) and 
confirmed using a Van Gieson stain (Figure 2c).  
Gene expression 
The abnormal adipose histology was reflected in the pattern of gene expression. The 
expression of multiple groups of genes involved in fibrosis was altered (Figure 2d). Genes 
important for fibrin degradation were reduced including tissue plasminogen activator (PLAT) 
and plasminogen (PLG). The expression of pro-inflammatory cytokines varied including 
reduction in IL-4 and IL-13 that are involved in promoting a pro-inflammatory macrophage 
population, as well as reductions in Endothelin-1 (EDN1) and connective tissue growth factor 
(CTGF) (fibroblast/myofibroblast activators). Furthermore, mRNA expression of 
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transforming growth factor-β3 (TGF-β3) was also decreased. In contrast, the expression of 
the genes encoding the chemotactic proteins, CCL2 and CCL3 (chemokine (C-C motif) 
ligand 2 and 3) increased.  
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Discussion  
We have carried out the largest and most detailed metabolic and hepatic phenotypic 
description of patients with AS to date. Our study highlights that patients with AS are at an 
increased risk of advanced NAFLD and cirrhosis, which seems disproportionate to age, BMI 
and duration of diabetes. Our results indicate that their extreme insulin resistance and its 
attendant complications such as advanced NAFLD and cardiovascular events occur at a very 
young age in the presence of disorganised and dysfunctional adipocytes.  
Consistent with previous data we have observed high levels of obesity and insulin resistance 
in AS patients. There are similarities between the clinical and biochemical profiles of 
individuals with AS and those with common obesity [1]. In contrast to common obesity, 
patients with AS invariably have childhood onset obesity, severe insulin resistance and very 
early occurrence of coronary heart disease before the age of 40 [11]. 
NAFLD ranges from relatively benign steatosis to cirrhosis. Our data revealed that a large 
proportion of patients with AS have evidence of NAFLD and advanced fibrosis at an early 
age. This supports published case reports and series that reveal unexpectedly high incidence 
of liver cirrhosis and associated mortality in Alström patients [1,15,16,21,22]. Our data, 
supports the need for early screening of liver fibrosis in patients with AS. Due to the rarity of 
the condition it is very difficult to validate the use of non-invasive markers of fibrosis in this 
setting. However, given the consistent accuracy and reproducibility of liver elastography 
(Fibroscan) in other liver diseases, we would advocate its use in AS to identify those in need 
of closer monitoring (i.e. for portal hypertension, liver cancer) and intensive metabolic 
optimisation. 
Accelerated liver disease has also been reported in patients with lipodystrophies [13], and 
indeed this has been reported to be a major contributor to premature mortality in these 
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disorders.  Like AS lipodystrophies are characterized by severe dyslipidaemic insulin 
resistance with attendant complications, and are exquisitely sensitive to variations in caloric 
and fat intake [23]. In contrast to AS, lipodystrophies are defined by partial or complete 
absence of adipose tissue, and often, though not always, feature low levels of adipocyte-
derived hormones such as leptin. Lipodystrophies have thus been cited as monogenic 
evidence of the "adipose expandability" hypothesis [13,14,24]. Importantly, in some 
lipodystrophies, severe NAFLD arises even though the functional defect is restricted to 
adipose tissue, proving that NAFLD is not necessarily a liver autonomous process. 
Unlike lipodystrophies, AS has been reported to feature excess obesity with abundant adipose 
tissue. It is plausible, however, that an adipose autonomous pro-fibrotic tendency in AS leads 
to a state of "relative" adipose failure more akin to the metabolic disease seen at high levels 
of "common" obesity.  In keeping with this, patients with AS, like "common" obesity 
patients, can successfully ameliorate metabolic syndrome with lifestyle changes to offload 
adipose tissue [23]. The histological studies we report in a subset of AS patients may provide 
tissue-level support for this hypothesis: The increase in adipose tissue fibrosis may impair 
adipose lipid storage, increasing the likelihood of ‘spill-over’. This is supported by increasing 
evidence of the adverse impact of adipose tissue fibrosis on metabolic flexibility [25], and 
recently published data suggest that adipose tissue fibrosis contributes to hepatic steatosis 
[26]. One example of this in a model organism is afforded by collagen VI-null ob/ob mice 
where reduced adipose tissue extracellular matrix permitted increased adipose depot size and 
adipocyte hypertrophy in response to high fat diet, and conferred metabolic protection even 
in the face of hyperphagia driven by leptin deficiency [25]. 
The pattern of gene expression that we observed in the adipose tissue was complex although 
several of the altered genes have been implicated in the pathogenesis of fibrosis, adipose 
dysfunction and global metabolic homeostasis.  The TGF-β / BMP7 pathway is an important 
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regulator of fibrogenesis and we observed decreased expression of TGF-β3 and BMP7 in 
adipose tissue from AS patients. BMP7 inhibits fibrogenesis [27] and, although TGF-βs are 
predominantly profibrotic, TGF-β3 supports tissue repair and limits scar formation [28] . 
BMP7 also has metabolic effects on the adipose tissue driving adipogenesis in mesenchymal 
stem cells [29] and increasing mitochondrial activity and fatty acid oxidation in brown 
adipose tissue [30]. Additionally, it is an anorectic factor with a decrease in food intake [31] 
as well as increased energy expenditure [32] contributing to weight loss in mice with 
increased BMP7. 
CCL2, whose expression was increased, has been implicated in steatohepatitis and metabolic 
dysfunction. CCL2 null mice have reduced hepatic fibrosis and markers of oxidative stress on 
a methionine/choline-deficient diet [33]. CCL2 overexpression leads to adipose inflammation 
and macrophage accumulation, systemic insulin resistance and hepatic steatosis [34].  
The precise role of ALMS1 in adipocytes is not fully understood with expression falling early 
in differentiation yet unchanged by differentiation modulating agents [35]. Knockdown 
experiments have shown that reduced ALMS1 expression decreases adipogenesis with 
preserved insulin action [8]. ALMS1 knockout mice gain weight rapidly on an obesogenic 
diet (6 weeks) with adipose tissue mass expansion. However, over time, adipose tissue mass 
fails to expand further, contrasting with observations in wild type animals, and increasing 
body weight is driven by increased hepatic lipid loading [6]. ALMS1 has also been shown to 
regulate fibroblast function. In dermal fibroblasts derived from patients with AS, extracellular 
matrix production including collagen production was increased and the cells resisted 
apoptosis [36]. 
Given the available pre-clinical data the adipose phenotype that we have characterized may 
represent a combination of effects both on adipocyte development, but also modification of 
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the inflammatory and fibrotic response. The net effect is likely to be an impaired ability of 
adipocytes to effectively store lipid that may then be delivered to the liver to fuel the 
development of advanced NAFLD. 
There are several limitations of the present study.  Firstly, although our single-centre national 
service is the largest centre in the world, the ultra-rare nature of the syndrome led to the small 
numbers of study subjects precluded the ability to analyse clinical variables that may predict 
NAFLD progression to fibrosis within AS (i.e. multi-variate analysis). Although as in our 
cohort 28/29 (96.6%) patients had biallelic nonsense or frameshift mutations we have not 
found evidence that site of mutation dictates the extent of liver disease. Secondly, as this is a 
cross-sectional study not all patients’ data is complete. However, as we were able to 
undertake several indices (biomarkers, transient elastography and histology) to assess the 
nature of NAFLD, we are able to offset missing variables. Thirdly, the control adipose 
biopsies were taken from female volunteers, however they were age and BMI matched. 
Finally, there is growing interest in genetic variants associated with NAFLD and in particular 
in patatin like phospholipase domain containing 3 (PNPLA3) which is associated not only 
with hepatic steatosis but in progression to fibrosis [37]. Additional genetic tests were beyond 
the scope of this study and would not alter the management of our patients who develop liver 
fibrosis at a much younger age than those seen in genome wide association studies. In 
general, its strengths lie: a) in the coherence of the patient group for an extremely rare 
monogenic metabolic disease; b) the in-depth characterisation of NAFLD and c) the link with 
adipose tissue structural and gene expression study. 
In conclusion, our study highlight the importance of detailed assessment of the liver in 
patients with AS, as many harbour asymptomatic advanced fibrotic disease. This may have 
relevance to other related ciliopathies including Bardet Biedl syndrome where similar 
mechanisms may operate [38]. It is possible that adipose tissue dysfunction is an important 
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contributor to the severe NAFLD that we have described, but a causal link cannot be 
conclusively demonstrated from our cohort. Further studies are warranted to define the 
precise molecular pathways that are responsible for these observations in both liver and 
adipose tissue, and this may ultimately lead to the identification of regulatory pathways and 
novel therapeutic targets for the treatment of NAFLD.  
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Figure legends 
Figure 1. Liver histology from a patient with Alström syndrome Representative histology 
is shown for patient 15. A. 200 x magnification image of H&E stain showing macrovesicular 
steatosis and inflammation, inset panel is staining for cytokeratin. B. 200 x magnification 
image of Sirius Red stain. 
Figure 2. Abdominal subcutaneous adipose tissue gene expression is deregulated in 
patients with Alström syndrome (n=6). Representative histological sections are presented 
in panels A-C (A. Control adipose H & E staining, B. Alström syndrome adipose H & E 
staining, C.  Alström syndrome adipose Van Gieson staining D.) gene expression in panel E. 
(PLG=plasmingogen, PLAT=tissue plasminogen activator, ILIα= interleukin 1α, 
IL4=interleukin 4, IL13=interleukin 13, IL13RA2=interlukin 13 receptor α 2, CCL2= 
chemokine ligand 2, CCL3= chemokine ligand 3, CCL11=chemokine ligand 11, 
IFNϒ=intergeron ϒ, EDN1= endothelin 1, CTGF=connective tissue growth factor, MMP-1= 
matrix metallopeptidase 1, MMP-3= matrix metallopeptidase 3, BMP7= bone morphogenetic 
protein 7, TGF-β3= transforming growth factor β 3, LTBP=latent transforming browth factor 
β binding protein 1, INHBE=inhibin β E, VEGFA=vascular endothelial growth factor A). 
Table 1. The demographic and metabolic characteristics of 30 patients with Alström 
syndrome (BMI=body mass index; HbA1c=glycosylated haemoglobin; BP=blood pressure; 
HDL=high density lipoprotein cholesterol) 
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Table 2. The hepatic phenotype of 30 patients with Alström Syndrome. (M=male; 
F=female; N=no; Y=yes; Spleen=spleen enlarged; AST= aspartate aminotransferase; 
ALT=alanine aminotransferase; Plts=platelets; ELF=Enhanced liver fibrosis panel; None=not 
suggestive of fibrosis; Mod=predictive of moderate fibrosis; Severe=predictive of severe 
fibrosis; LSE=liver stiffness evaluation; NP=not predictive of fibrosis; Predictive=predictive 
of fibrosis; IQ=interquartile range; *Patients with liver histology available). 
Table 3. Histological analysis of livers of patients with Alström syndrome. (M=male; 
F=female; IQR=interquartile range; NP=not predictive of fibrosis; NAS=non alcoholic fatty 
liver disease activity score.) 
 
 
 
 
 
Table 1. The demographic and metabolic characteristics of 30 patients with Alström syndrome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
n (Male/Female) 30 (21/9) 
Age 24 (21.25-37) 
BMI (kg/m2) 29.3 (25.95-34.05) 
Fat mass (kg) 20.3 (18.4-27.2) 
Lean mass (kg) 59.2 (49.2-67.2) 
Diabetes  24/30 
HbA1c (mmol/mol;%) 52 (40-70); 6.9 (5.8-8.6) 
Systolic BP (mmHg) 121 (111-127) 
Diastolic BP (mmHg) 74 (67.5-80) 
C-Peptide/Glucose 
(ng/ml)/(mg/dl) 
0.047 (0.027-0.088) 
Total cholesterol 
(mmo/l) 
4.95 (4.2-6.3) 
HDL (mmol/l) 0.89 (0.75-1.06) 
Triglycerides (mmol/l) 3.25 (2.1-4.75) 
Table 2. The hepatic phenotype of 30 patients with Alström Syndrome.  
ID Age Sex Ultrasound 
 
 
AST 
IU/L
ALT 
IU/L
AST
/ 
ALT
Plts Albu
-min 
g/L 
Biliru
-bin 
µmol/
L 
ELF 
 
 
Fibroscan 
 
 
 
Texture Contour 
Irregular 
Splee-
n  
Liver 
lesion
Value 
 
Descr
i-ptor 
LSE 
(IQR) 
Descriptor 
 
1 24 M Normal N N N 29 33 0.87 210 47 4 8.721 Mod   
2 27 M Normal N N N 32 37 0.86 180 45 3 8.750 Mod 7.8 (0.9) NP 
3 40 M Normal N N N 18 17 1.05 221 45 3     
4 23 F Fatty N N N 11 21 0.52 307 44 5 8.344 Mod 4.4 (1.0) NP 
5 30 F Normal N N Y 49 73 0.67 324 49 8 9.340 Mod 9.0 (1.7) Predictive 
6 44 M Coarse Y N N 25 53 0.47 151 40 5 9.903 Severe 4.8 (1.3) NP 
7 30 M Fatty N N N 29 83 0.34 244 55 5 7.732 Mod 5.1 (1.4) NP 
8 22 M Fatty N N N 29 109 0.26 244 47 6 9.294 Mod 12.6 (1.6) Predictive 
9 34 F Fatty N N N 16 25 0.64 308 44 4 9.740 Mod   
10* 19 M Fatty N N N 38 76 0.5 164 45 4 9.280 Mod   
11* 19 M Fatty Y Y N 32 48 0.66 236 54 5 7.590 None 13.9 (1.9) Predictive 
12*  M Fatty N N N 34 77 0.44 129 41 11 10.13 Severe 6.3 (0.7) NP 
13 22 M Fatty N N N 44 76 0.57 292 48 9 8.622 Mod 5.1 (1.6) NP 
14 20 M Normal N N N 32 43 0.74 247 47 4 10.28 Severe 6.0 (1.8) NP 
15* 19 M Fatty N Y N 35 76 0.46 183 44 7    11.1 (2) Predictive 
16 22 M Fatty N Y N 58 142 0.40 244 49 5 10.28 Severe 11.8 (0.2) Predictive 
17 21 M Fatty N Y N 126 209 0.60 300 47 4 9.489 Mod   
18  M Coarse Y N N 55 29 1.89 92 36 5 9.527 Mod 9.2 (1.8) Predictive 
19 20 M Fatty N N N N/A   225 47 5    5.2 (0.9)  
  
 
 
 
 
 
 
20 20 F Normal N N N 18 19 0.94 144 45 6 9.643 Mod 4.2 (1) NP 
21 27 F Normal N N N 17 16 1.06 201 43 5 8.075 Mod 7.2 (1.9) NP 
22 22 F Fatty N N N 26 66 0.39 254 46 6 10.16 Severe 14.4 (0.4) Predictive 
23 51 M Coarse Y N N 28 37 0.75 240 49 4 10.31 Severe 9.6 (1.3) Predictive 
24 21 M Fatty N N N 34 67 0.50 280 46 9 8.673 Mod 4.9 (1.3) NP 
25 47 M Fatty N N N 17 21 0.81 203 48 10 7.922 Mod 12.9 (2.9) Predictive 
26 21 F Cirrhotic Y Y N 27 34 0.79 274 45 7 9.852 Severe 13 (2.9) Predictive 
27* 25 M Fatty Y Y Y 96 65 1.47 208 39 32     
28* 41 M     31 80 0.38 133 43 31 12.4 Severe   
29* 23 M     73 50 1.46 36 35 28     
30* 39 F     49 46 1.07 154 40 6 9.48 Mod   
Table 3. Histological analysis of livers of patients with Alström syndrome.  
ID Gender Sample ELF Fibroscan Liver biopsy interpretation 
Value Descriptor Value 
(IQR) 
Descriptor Steatosis InflammationBallooning Total 
NAS 
Kleiner 
Fibrosis 
Comment 
10 M Biopsy 9.280      3 1 2 6 1c Steatohepatitis 
11 F Biopsy 7.590 None 13.9 (1.9) Predictive 2 1 1 4 3 Steatohepatitis. 
Early bridging. 
   
12 
M Post 
mortem 
10.13 Severe 6.3 (0.7) NP 1 0 0 1 1c change, does not 
amount to SH, 
mild portal 
fibrosis only 
15 M Biopsy     11.1 (2) Predictive 1 1 1 3 3 Steatohepatitis 
 27 M Post 
mortem 
        1 1 2 4 4 In keeping with 
end stage 
Steatohepatitis. 
 






Supplementary Table S1. The ALMS1 mutations of the patients with Alström 
syndrome. 
 
 
ID Mutation 
1 c.2041C>T / c.2041C>T 
2 c.6823C>T / c.9535C>T 
3 c.2822T>A / c.10775delC 
4 c6584delA / c.8832C>G 
5 c.8002C>T / c.10879C>T 
6 c.8995C>T / c.9001C>T 
7 c.6895delG / c.6895delG 
8 c.6526C>T / c.11101C>T 
9 c.11101C>T 
10 c.10769delC / c.5356A>G 
11 c.6823C>T / c.9535C>T 
12 c.1729delA / c.10477C>T 
13 c6526C>T / c.11101C>T 
14 c.8932C>T / c.5356A>G 
15 c.4937C>A 
16 c.7544-200_767+1110del / c.7544-
200_767+1110del 
17 c.4937C>A / c.4937C>A 
18 c.10769delC / c.11410C>T 
19 c.7544-200_767+1110del / c.7544-
200_767+1110del 
20 c.2041C>T / c.2041C>T 
21 c.2218dupA / c.1069C > T 
22 c.5075delC / c.5075delC 
23 c.10483C>T / c.10775delC 
24 c.6526C>T / c.11101C>T 
25 c.1874A>G 
26 c.7911dupC 
27 c.10769delC/c.10986G>A 
28 c.10769delC / c.10477C>T 
29 Not available 
30 c.10775delC /  
 
 
Supplementary Table S2. Clinical characteristics of 6 patients with Alström syndrome 
and 9 controls who underwent abdominal subcutaneous adipose tissue biopsy. 
(BMI=body mass index; HDL=high density lipoprotein cholesterol, ALT=Alanine 
aminotransferase, AST=Aspartate transaminase, ELF=Enhanced liver fibrosis panel) 
(*p<0.05) 
Clinical characteristics Alström syndrome 
(n=6) ;(Cohort) 
Control (n=9) 
Age (years) 22 (20.5-23.5) ; 24 (21.3-
37) 
31 (25-35) 
Gender (male/female) 4/2 ; 21/9 0/9 
BMI (kg/m2) 29 (26-33.6); 29.3 (26-34) 26.6 (23.6-35.1) 
Diabetes (%) 100% ; 80% 0% 
HbA1c (mmol/mol)/(%) 47.5 (40.25-60)/6.5 (5.8-
7.6)*; 52 (40-70)/ 6.9 (5.8-
8.6) 
35 (34-37)/5.4 (5.3-5.5) 
Total cholesterol (mmol/L) 4.9 (4.35-5.075); 5 (4.2-6.3) 5.2 (4.5-5.6) 
HDL cholesterol (mmol/L) 0.67 (0.66-0.74); 0.89 
(0.75-1.06) 
1.5 (1.1-1.9) 
Triglycerides (mmol/L) 3.4 (2.7-4.3)*; 3.3 (2.1-
4.75) 
0.75 (0.7-1.4) 
ALT (IU/L) 66 (48-76)*; 50 (33-76) 13.5 (10.75-18) 
AST (IU/L) 29 (28-32) *; 32 (26-44) 15.5 (15-16.75) 
ELF (4/6) 
   None to mild 
   Moderate 
   Severe 
 
- 
2 
2 
 
FibroScan® (6/6) 
  < 8 kPa  
  ≥ 8 kPa 
 
1 
5 
 
 
